Premium
Effects of prophylactic chemotherapy for postmolar trophoblastic disease in patients with complete hydatidiform mole
Author(s) -
Ayhan A.,
Ergeneli M.H.,
Yüce K.,
Yapar E.G.,
Kisnisci A.H.
Publication year - 1990
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/0020-7292(90)90980-y
Subject(s) - medicine , gynecology , chemotherapy , gestational trophoblastic neoplasia , obstetrics , disease , gestational trophoblastic disease , pregnancy , gestation , biology , genetics
An analysis of 233 patients with complete hydatidiform mole admitted to Hacettepe University Hospital between 1964 and 1988 has been carried out. Methotrexate was administered prophylactically to 19 of 120 low‐risk and to 52 of 113 high‐risk patients. The difference in the incidence of postmolar gestational trophoblastic disease between prophylactically untreated and treated groups of either low‐risk (13.9% versus 5.3%, P > 0.01) or high‐risk (26.2% versus 25.0%, P > 0.01) patients was found to be statistically insignificant. Drug toxicity and mortality rates were 16.9% and 2.8%, respectively. It is concluded that prophylactic chemotherapy is not highly effective in the prophylaxis of postmolar gestational trophoblastic disease. Strict follow‐up through sensitive betahuman chorionic gonadotropin assays should be the standard management of postmolar patients.